Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03959891
Title AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Massachusetts General Hospital

Her2-receptor negative breast cancer


Fulvestrant + Ipatasertib + Palbociclib


Fulvestrant + Ipatasertib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.